Recently, Lu Pengqi, Vice Commissioner of the China National Intellectual Property Administration, met with a delegation led by Severin Schwan, Chairman of the Board of Directors of Switzerland's Roche Group, in Beijing. Lu Pengqi emphasized that the China National Intellectual Property Administration is committed to treating the intellectual property rights of both domestic and foreign-funded enterprises with equality, providing them with the same level of protection in strict accordance with the law. Moving forward, the administration will persist in fostering positive exchanges and collaborations with countries around the world. Severin Schwan remarked that intellectual property rights constitute the core competitiveness of innovative pharmaceutical companies. With China's well-established intellectual property protection system, multinational pharmaceutical companies are brimming with confidence in the Chinese market. Roche Group is poised to ramp up its R&D investment in China and actively facilitate the global dissemination of China's pharmaceutical innovation achievements.